CD79a Monoclonal Antibody (24C2.5), eFluor™ 660, eBioscience™, Invitrogen™

Description

• This 24C2.5 MAb reacts with the intracellular tail of mouse CD79a (also known as Ig alpha or mb-1), a signaling component of the B cell receptor (BCR)
• CD79a heterodimerizes with CD79b (Ig beta, B29), and together with surface Ig, make up the BCR
• Both CD79 subunits consist of a single extracellular Ig domain, a transmembrane domain, and an intracellular signaling domain
• CD79a is expressed almost exclusively on B cells, as well as in most B lineage acute lymphoblastic leukemias
• The cytoplasmic domain of CD79a contains immunoreceptor tyrosine-based activation motifs (ITAMs), which constitute the signal transducing portions of the BCR
• Tyrosine phosphorylation of these ITAMs by Syk and Lyn initiates numerous signaling cascades, resulting in B cell activation, proliferation, and differentiation
• CD79a is a disulphide-linked heterodimer that includes B29 (CD79b) polypeptide
• CD79a is a B lymphocyte antigen receptor with an antigen-specific surface component Ig (immunoglobulin) that associates with Ig-alpha and Ig-beta, necessary elements for the expression and function of the B-cell antigen receptor
• CD79a first appears at pre-B cell stage and persists until the plasma cell stage where it is found as an intracellular component
• CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas
• It is not present in myeloid or T cell lines
• Diseases associated with CD79a include Agammaglobulinemia 3 and Agammaglobulinemia, Non-Bruton type.